Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Actelion issues invitation to 2016 Annual General Meeting of Shareholders (Actelion Ltd)

$
0
0
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 6 April 2016- Actelion Ltd (SIX: ATLN) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Business Report of the year ending 31 December 2015 will be held on 4 May 2016 at 10.00 CEST at the Congress Center, Messe Basel, Switzerland. At this year's meeting the Board of Directors is proposing a dividend payment of CHF 1.50 per share, an increase of 15%. The Board is also proposing the reduction of share capital by cancelation of shares repurchased on a second trading line as part of the company's share repurchase program of up to 10...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>